Achieve Life Sciences
web2Achieve Life Sciences is a clinical stage pharmaceutical company developing cytisinicline as a...
About
Achieve Life Sciences is a clinical stage pharmaceutical company developing cytisinicline as a potential prescription treatment to help people stop smoking and overcome nicotine dependence. Cytisinicline acts on nicotine receptors involved in withdrawal symptoms and the reinforcing effects of tobacco use. The company has conducted late stage clinical trials evaluating smoking cessation and has also investigated the treatment's potential for people seeking to stop using electronic cigarettes. Its development activities include clinical research, regulatory preparation, and planning for potential commercialization. Cytisinicline remains an investigational treatment in the United States, and commercial availability depends on regulatory approval.
Explore this sector
Exchange listings
Listing identities only. Orbitrum does not publish live prices or market performance on this public profile.
1 expert evaluated Achieve Life Sciences.
Experts evaluating Achieve Life Sciences
Explore the public profiles of experts who have evaluated this project.
Orbitrum Academy